OM Outset Medical, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1484612 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.6%
TTM net income YoY19.0%
TTM EPS YoY67.5%
Revenue 3-yr CAGR-2.6%
Net income 3-yr CAGR—
Margins
Gross margin42.0%
Operating margin-51.2%
Net margin-58.3%
FCF margin-35.2%
EBITDA margin-48.8%
Returns
ROE-63.0%
ROA-28.0%
ROIC (approx.)-28.3%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets63.8%
Debt / equity1.18x
Current ratio4.86x
Interest coverage-4.54x
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $33.60M | $31.64M | $27.86M | $28.87M | $29.43M | $31.42M | $29.75M | $29.47M |
| Cost of revenue | $19.93M | $18.35M | $15.77M | $16.64M | $17.84M | $19.55M | $18.69M | $18.72M |
| Gross profit | $13.67M | $13.28M | $12.10M | $12.23M | $11.59M | $11.87M | $11.07M | $10.75M |
| R&D expense | $5.90M | $5.45M | $5.62M | $5.05M | $5.38M | $5.29M | $5.51M | $7.89M |
| SG&A expense | $8.31M | $11.36M | $10.12M | $11.93M | $8.48M | $9.16M | $8.30M | $9.27M |
| Operating income | -$12.27M | -$15.68M | -$16.92M | -$17.63M | -$15.81M | -$16.86M | -$16.40M | -$21.86M |
| Interest expense | $3.50M | $3.44M | $3.37M | $3.44M | $3.48M | $3.48M | $3.56M | $5.83M |
| Pretax income | -$14.53M | -$17.76M | -$18.76M | -$19.40M | -$17.43M | -$18.44M | -$25.67M | -$25.64M |
| Income tax | $153,000 | $220,000 | $217,000 | $95,000 | $404,000 | $104,000 | $115,000 | -$4,000 |
| Net income | -$14.69M | -$17.98M | -$18.98M | -$19.49M | -$17.84M | -$18.54M | -$25.78M | -$25.64M |
| EBITDA | -$11.60M | -$15.05M | -$16.12M | -$16.75M | -$14.80M | -$15.71M | -$15.11M | -$20.45M |
| EPS (basic) | -0.78 | -0.97 | -1.03 | — | -1.00 | -1.04 | -3.66 | — |
| EPS (diluted) | -0.78 | -0.97 | -1.03 | — | -1.00 | -1.04 | -3.66 | — |
| Weighted avg. shares (diluted) | 18,831 | 18,619 | 18,373 | — | 17,783 | 17,743 | 7,038 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $33.94M | $35.01M | $30.56M | $35.01M | $36.44M | $39.56M | $75.93M | $124.01M |
| Short-term investments | $102.69M | $112.19M | $126.14M | $133.94M | $142.20M | $144.53M | $113.07M | $34.67M |
| Receivables | $30.41M | $29.22M | $25.32M | $28.33M | $32.96M | $34.89M | $36.89M | $35.62M |
| Inventory | $44.99M | $47.31M | $49.65M | $47.61M | $49.29M | $52.25M | $55.77M | $59.39M |
| Current assets | $216.22M | $227.85M | $236.71M | $250.88M | $265.37M | $275.58M | $286.56M | $258.22M |
| PP&E, net | $3.54M | $3.71M | $4.07M | $4.67M | $5.25M | $6.17M | $6.94M | $8.13M |
| Total assets | $230.41M | $242.38M | $249.45M | $264.50M | $277.25M | $288.80M | $301.21M | $275.80M |
| Current liabilities | $44.45M | $43.89M | $37.61M | $37.63M | $37.45M | $36.91M | $34.22M | $45.38M |
| Long-term debt | $98.37M | $97.65M | $96.94M | $96.24M | $95.52M | $94.81M | $94.11M | $197.38M |
| Total debt | $98.37M | $97.65M | $96.94M | $96.24M | $95.52M | $94.81M | $94.11M | $197.38M |
| Total liabilities | $147.09M | $146.05M | $137.77M | $137.54M | $134.89M | $134.02M | $131.34M | $248.98M |
| Shareholders' equity | $83.31M | $96.34M | $111.69M | $126.95M | $142.37M | $154.78M | $169.87M | $26.82M |
| Net debt | $64.43M | $62.64M | $66.38M | $61.23M | $59.09M | $55.26M | $18.19M | $73.36M |
| Shares outstanding | 18.87M | 18.80M | 18.53M | 18.17M | 17.81M | 17.77M | 17.72M | 3.53M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10.38M | -$9.63M | -$12.84M | -$9.52M | -$6.32M | -$4.82M | -$25.66M | -$16.49M |
| Capital expenditure | $109,000 | $111,000 | $65,000 | $223,000 | $160,000 | $292,000 | $123,000 | $43,000 |
| Free cash flow | -$10.49M | -$9.75M | -$12.91M | -$9.74M | -$6.48M | -$5.12M | -$25.79M | -$16.53M |
| Investing cash flow | $9.66M | $14.17M | $7.90M | $8.59M | $2.97M | -$31.16M | -$78.08M | $108.15M |
| Financing cash flow | -$56,000 | -$88,000 | $501,000 | $0 | $231,000 | -$384,000 | $55.66M | -$938,000 |
| Depreciation & amortization | $666,000 | $627,000 | $795,000 | $881,000 | $1.01M | $1.16M | $1.29M | $1.41M |
| Stock-based compensation | $1.69M | $2.70M | $3.45M | $4.06M | $5.08M | $3.50M | $2.98M | $4.95M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.